2021 年第 5 期 第 16 卷

医院2017—2019年重点监控药品管控成效分析

Analysis on the effectiveness of management and control of key monitoring drugs in hospital from 2017 to 2019

作者：陈旭汤波周月张弦田晶晶张华朱锡玲王晓娟

英文作者：Chen Xu Tang Bo Zhou Yue Zhang Xian Tian Jingjing Zhang Hua Zhu Xiling Wang Xiaojuan

单位：安徽省淮南市第一人民医院药学部232007

英文单位：Department of Pharmacy Huainan First People′s Hospital Anhui Province Huainan 232007 China

关键词：重点监控药品；管控成效；合理用药

英文关键词：Keymonitoringdrugs;Effectivenessofcontrol;Rationaldrugsuse

• 摘要：

• 目的 分析2017—2019年医院重点监控药品的管控成效。方法 以安徽省临床路径检查时的辅助用药品种确定安徽省淮南市第一人民医院重点监控药品品种，对本院重点监控药品的品种结构、金额占比、用药金额前10位重点监控药品的用药频度、限定日费用、序号比（销售金额序号/用药频度序号）等指标进行分析，其中2017年为干预前用药情况，2018年、2019年数据为干预后用药情况。比较医院干预前后重点监控药品的管控成效。结果 本院3年来重点监控药品管理取得一定成效，管控后重点监控药品销售金额逐年下降，重点监控药品销售金额占药品销售总金额构成比分别为11.28%（2 437.24/21 606.23）、7.00%（1 706.74/24 393.49）、5.18%（1 551.70/29 941.20），差异有统计学意义（P<0.001）。年递减率2018、2019年分别为29.97%、9.08%，差异有统计学意义（P<0.001）。重点监控药品抽样处方评价合理率逐年提高，但仍存在不合理用药现象。结论 本院重点监控药品管理取得一定成效，但仍然存在不合理用药问题，医院应在此基础上继续进行精细化过程管理，切实减轻患者用药负担，提高医院合理用药水平。

• Objective To analyze the effectiveness of management and control of key monitoring drugs in hospital from 2017 to 2019. Methods The varieties of key monitoring drugs were determined in Huainan First People′s Hospital, Anhui Province by auxiliary drugs at the examination of Anhui clinical pathway inspection. The variety structure, amount proportionality of the key monitoring drugs, the top 10 key monitoring drugs in the amount of drug use frequency, limited daily cost, serial number ratio(sales amount serial number/drug use frequency serial number) and other indicators were analyzed. Those indicators in 2017 were collected before intervention, and in 2018 and 2019 after intervention. The control effectiveness of key monitoring drugs before and after intervention was compared. Results In the past 3 years, our hospital achieved remarkable results in the management of key monitoring drugs. The sales amount of key monitoring drugs decreased year by year after intervention. The composition ratio of key monitoring drugs sales amount to total drug amount was 11.28%（2 437.24/21 606.23）, 7.00%（1 706.74/24 393.49）, 5.18%（1 551.70/29 941.20）, and the difference was statistically significant(P<0.001). Annual decline rates in 2018 and 2019 were 29.97% and 9.08%, and the difference was statistically significant(P<0.001). The reasonable rate of sampling prescription evaluation of key monitoring drugs increased year by year, but there was still unreasonable drugs use. Conclusions The management of  key monitoring durgs in our hospital achieves remarkable results, but there still has unreasonable drugs use. On this basis, the hospital should continue to carry out refined process management, effectively reduce the drugs burden of patients and improve the rational drugs use.